NeuroSearch

NeuroSearch A/S is a leading CNS focused and European based biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S (NEUR). The company's core business is development of novel drugs to treat diseases of the central nervous system, and the pipeline comprises eight products in clinical development (Phase I-III). These include Huntexil^® (pridopidine), a unique orphan drug in Phase III development for the treatment of Huntington’s disease, and tesofensine ready for Phase III development as a novel treatment of obesity. 

NeuroSearch is founded on a well-established drug discovery platform in the field of small molecule pharmacology, ion channels and monoamine transporters, ensuring the continuous production of novel preclinical development candidates. The company has strategic drug discovery alliances with Janssen Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott. Further, NeuroSearch has equity interests in a number of private companies in the Life Science industry.